fda takes tirzepatide off shortage list Lilly's weight-loss drug removed from FDA's Drug Shortages Infographic | FDA

They extend the usable life of multi-dose vials by minimizing contamination introduction

The future of weight loss with tirzepatide looks promising, offering hope for those struggling with obesity and related health issues

This once-weekly medication, approved for type 2 diabetes and chronic weight management, has a five-day half-life that provides some scheduling flexibility

For researchers prioritizing regulatory certainty, real-world safety data, and established protocols, Tirzepatide remains the gold standard in the GLP-1 agonist class as of 2026

Chronic stress raises cortisol, which can interfere with weight loss and promote fat storage around the midsection